Related content

An integrated pharmacokinetic–pharmacodynamic model for an Aurora kinase inhibitor

By Kamei Hiroko   Jackson Robert   Zheleva Daniella   Davidson Fordyce  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 37, Iss. 4, 2010-08 ,pp. : 407-434

Springer Publishing Company

Access to resources Recommend Favorite

Bayesian Calibration of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Carbaryl Cholinesterase Inhibition

By Nong Andy   Tan Yu-Mei   Krolski Michael   Wang Jiansuo   Lunchick Curt   Conolly Rory   Clewell Harvey  

Journal of Toxicology and Environmental Health, Vol. 71, Iss. 20, 2008-01 ,pp. : 1363-1381

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Pharmacokinetic–Pharmacodynamic Model for Neuromuscular Blocking Agents to Predict Train-of-Four Twitches

By Eleveld Douglas J.   De Haes Ann   Proost Johannes H.   Wierda J. Mark K. H.  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 30, Iss. 2, 2003-04 ,pp. : 105-118

Springer Publishing Company

Access to resources Recommend Favorite

Validation of a population pharmacokinetic/pharmacodynamic model for 5 -reductase inhibitors

By Trouw R.A.J.   De Wit M.J.   Olsson Gisleskog P.   Hermann D.   Hammarlund-Udenaes M.   Karlsson M.O.  

European Journal of Pharmaceutical Sciences, Vol. 8, Iss. 4, 1999-08 ,pp. : 291-299

Elsevier

Access to resources Recommend Favorite

A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia

By Olesen Anne E.   Upton Richard  

Clinical Pharmacokinetics, Vol. 49, Iss. 12, 2010-12 ,pp. : 817-827

Adis International

Access to resources Recommend Favorite